Xiang Nan, Li Yu-Jing, Liu Meng-Yao, Wu Qi-Qin, Zhang Ya-Xin, Jin Hui-Zhi, Wang Qian, Li Yu-Wei, Tong Da-Li, Xue Tian, Jin Teng-Chuan, Bao Wei, Chen Zhu
Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Rheumatol Adv Pract. 2023 Jul 24;7(2):rkad064. doi: 10.1093/rap/rkad064. eCollection 2023.
The surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron infections has affected most Chinese residents at the end of 2022, including a number of patients with systemic autoimmune rheumatic diseases (SARDs).
To investigate the antibody level of the Omicron variant in SARD patients after SARS-CoV-2 Omicron infection, we tested BA.5.2 and BF.7 Omicron variant IgG antibody levels using ELISA on blood samples collected from 102 SARD patients and 19 healthy controls (HCs). The type of SARD, demographics, concurrent treatment, doses of SARS-CoV-2 vaccines and outcomes were also recorded.
A total of 102 SARD patients (mean age: 40.3 years; 89.2% female), including 60 SLE, 32 RA and 10 other SARDs, were identified. Of these, 87 (85.3%) were infected with SARS-CoV-2. We found that the BA.5.2 and BF.7 antibody levels of infected SARD patients were lower than those of HCs (<0.05). Sixty-five (63.7%) patients had at least one dose of a SARS-CoV-2 vaccine. SARD patients with at least two doses of SARS-CoV-2 vaccine had a higher level of BA.5.2 and BF.7 antibodies than the unvaccinated group (<0.05). There was no evidence for a significant inhibitory effect of glucocorticoids (GCs) on the BA.5.2 and BF.7 Omicron variant antibody levels in SARD patients. SLE patients using biologic DMARDs had a lower BA.5.2 Omicron variant antibody level than patients using GCs and/or HCQ.
These data suggest that patients with SARDs had a lower antibody response than HCs after Omicron infection.
2022年末，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株奥密克戎感染激增，影响了大多数中国居民，包括一些系统性自身免疫性风湿病（SARDs）患者。
为了调查SARD患者在感染SARS-CoV-2奥密克戎变异株后的抗体水平，我们采用酶联免疫吸附测定法（ELISA）检测了102例SARD患者和19名健康对照（HCs）血液样本中的BA.5.2和BF.7奥密克戎变异株IgG抗体水平。还记录了SARD的类型、人口统计学特征、同时进行的治疗、SARS-CoV-2疫苗接种剂量和结果。
共确定了102例SARD患者（平均年龄：40.3岁；89.2%为女性），其中包括60例系统性红斑狼疮（SLE）、32例类风湿关节炎（RA）和10例其他SARDs。其中，87例（85.3%）感染了SARS-CoV-2。我们发现，感染的SARD患者的BA.5.2和BF.7抗体水平低于健康对照（P<0.05）。65例（63.7%）患者至少接种了一剂SARS-CoV-2疫苗。至少接种两剂SARS-CoV-2疫苗的SARD患者的BA.5.2和BF.7抗体水平高于未接种组（P<0.05）。没有证据表明糖皮质激素（GCs）对SARD患者的BA.5.2和BF.7奥密克戎变异株抗体水平有显著抑制作用。使用生物性改善病情抗风湿药（DMARDs）的SLE患者的BA.5.2奥密克戎变异株抗体水平低于使用GCs和/或羟氯喹（HCQ）的患者。
这些数据表明，SARD患者在感染奥密克戎变异株后的抗体反应低于健康对照。
